Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 118

1.

Improved consistency in dosing anti-tuberculosis drugs in Taipei, Taiwan.

Chiang CY, Yu MC, Shih HC, Yen MY, Hsu YL, Yang SL, Lin TP, Bai KJ.

PLoS One. 2012;7(8):e44133. doi: 10.1371/journal.pone.0044133. Epub 2012 Aug 27. Erratum in: PLoS One. 2012;7(9). doi:10.1371/annotation/67e66370-247e-4406-b7a0-f0696d04e87e.

PMID:
22952900
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Inconsistent dosing of anti-tuberculosis drugs in Taipei, Taiwan.

Chiang CY, Bai KJ, Lee CN, Enarson DA, Suo J, Luh KT.

Int J Tuberc Lung Dis. 2010 Jul;14(7):878-83.

PMID:
20550772
[PubMed - indexed for MEDLINE]
3.

Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.

Thee S, Seddon JA, Donald PR, Seifart HI, Werely CJ, Hesseling AC, Rosenkranz B, Roll S, Magdorf K, Schaaf HS.

Antimicrob Agents Chemother. 2011 Dec;55(12):5560-7. doi: 10.1128/AAC.05429-11. Epub 2011 Oct 3.

PMID:
21968358
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Prescriptions and dosages of anti-tuberculosis drugs in the National Tuberculosis Control Programme of Malawi.

Harries AD, Gausi F, Salaniponi FM.

Int J Tuberc Lung Dis. 2004 Jun;8(6):724-9.

PMID:
15182142
[PubMed - indexed for MEDLINE]
5.

[Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].

Saito W, Nagayama N, Miyamoto M, Hara H, Suzuki J, Masuda K, Baba M, Tamura A, Nagai H, Akagawa S, Kawabe Y, Machida K, Kurashima A, Yotsumoto H.

Kekkaku. 2003 Oct;78(10):611-7. Japanese.

PMID:
14621568
[PubMed - indexed for MEDLINE]
6.

Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up.

Su WJ, Perng RP.

Int J Tuberc Lung Dis. 2002 Nov;6(11):1029-32.

PMID:
12475151
[PubMed - indexed for MEDLINE]
7.

Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations.

Verhagen LM, López D, Hermans PW, Warris A, de Groot R, García JF, de Waard JH, Aarnoutse RE.

Trop Med Int Health. 2012 Dec;17(12):1449-56. doi: 10.1111/tmi.12003. Epub 2012 Oct 24.

PMID:
23094704
[PubMed - indexed for MEDLINE]
Free Article
8.

Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children.

Ramachandran G, Hemanth Kumar AK, Bhavani PK, Poorana Gangadevi N, Sekar L, Vijayasekaran D, Banu Rekha VV, Ramesh Kumar S, Ravichandran N, Mathevan G, Swaminathan S.

Int J Tuberc Lung Dis. 2013 Jun;17(6):800-6. doi: 10.5588/ijtld.12.0628.

PMID:
23676165
[PubMed - indexed for MEDLINE]
9.

Pharmaceutical formulation of a fixed-dose anti-tuberculosis combination.

Danckwerts MP, Ebrahim S, Pillay V.

Int J Tuberc Lung Dis. 2003 Mar;7(3):289-97.

PMID:
12661846
[PubMed - indexed for MEDLINE]
10.

Drug prescribing practices for tuberculosis in Uzbekistan.

Hasker E, Khodjikhanov M, Usarova S, Asamidinov U, Yuldashova U, van der Werf MJ, Uzakova G, Veen J.

Int J Tuberc Lung Dis. 2009 Nov;13(11):1405-10.

PMID:
19861014
[PubMed - indexed for MEDLINE]
11.

Tuberculosis control programme guidelines--treatment regimens.

Durrheim DN, Belt EL.

S Afr Med J. 1996 Oct;86(10):1293-4. No abstract available.

PMID:
8955740
[PubMed - indexed for MEDLINE]
12.

Initial drug regimens for the treatment of tuberculosis: evaluation of physician prescribing practices in New Jersey, 1994 to 1995.

Liu Z, Shilkret KL, Finelli L.

Chest. 1998 Jun;113(6):1446-51.

PMID:
9631776
[PubMed - indexed for MEDLINE]
13.

Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.

Agrawal S, Singh I, Kaur KJ, Bhade SR, Kaul CL, Panchagnula R.

Int J Pharm. 2004 May 19;276(1-2):41-9.

PMID:
15113612
[PubMed - indexed for MEDLINE]
14.
15.

[Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].

Wada M.

Kekkaku. 2001 Jan;76(1):33-43. Review. Japanese.

PMID:
11211781
[PubMed - indexed for MEDLINE]
16.

Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.

Sharma SK, Singla R, Sarda P, Mohan A, Makharia G, Jayaswal A, Sreenivas V, Singh S.

Clin Infect Dis. 2010 Mar 15;50(6):833-9. doi: 10.1086/650576.

PMID:
20156055
[PubMed - indexed for MEDLINE]
Free Article
17.

Inadequate therapeutic response to a recommended antituberculosis fixed-dose combination regimen in an overweight patient with Mycobacterium bovis infection.

Lloret-Linares C, Mouly S, Hoang-Nguyen DT, Evans J, Raskine L, Lopes A, Cambau E, Bergmann JF, Sellier P.

Ann Pharmacother. 2013 Jan;47(1):e4. doi: 10.1345/aph.1R452. Epub 2013 Jan 16.

PMID:
23324515
[PubMed - indexed for MEDLINE]
18.

Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts.

Schechter M, Zajdenverg R, Falco G, Barnes GL, Faulhaber JC, Coberly JS, Moore RD, Chaisson RE.

Am J Respir Crit Care Med. 2006 Apr 15;173(8):922-6. Epub 2006 Feb 10.

PMID:
16474028
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Frequency of recurrence among MDR-tB cases 'successfully' treated with standardised short-course chemotherapy.

Migliori GB, Espinal M, Danilova ID, Punga VV, Grzemska M, Raviglione MC.

Int J Tuberc Lung Dis. 2002 Oct;6(10):858-64.

PMID:
12365571
[PubMed - indexed for MEDLINE]
20.

[Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years].

Brändli O, Haegi V, Villiger B, Bohn W, Baumann HR, Zäch R.

Schweiz Med Wochenschr. 1989 Mar 11;119(10):299-305. German.

PMID:
2652281
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk